From:	Ahmed, Narin
To:	Giordano, Erica; Patel, Manisha
Cc:	Riggins, Cindy
Subject:	RE: BL 125646 CMC Information Request
Date:	Tuesday, May 09, 2017 11:58:51 AM
Attachments:	image001.png response-fda-20170509.pdf
Sensitivity:	Confidential

Dear Erica,

Attached please find the response to the below request. This will be submitted as an official amendment to BLA 125-646.

Thanks.

Best regards,
Narin

Narin Ahmed (Hussain), Pharm.D.
Sr. Associate Director, Regulatory Affairs
Novartis Pharmaceuticals Corporation
Global Drug Development, CAR-T Program
One Health Plaza, 315/3650A
East Hanover, NJ 07936
USA
Phone +1-862-778-5739
Fax +1-973-781-7173
narin.ahmed@novartis.com
www.novartis.com

From: Giordano, Erica [mailto:Erica.Giordano@fda.hhs.gov]
Sent: Tuesday, May 02, 2017 12:41 PM
To: Patel, Manisha <manisha.patel@novartis.com>
Cc: Riggins, Cindy <cindy.riggins@novartis.com>; Ahmed, Narin <narin.ahmed@novartis.com>
Subject: BL 125646 CMC Information Request
Sensitivity: Confidential

Good afternoon,

Please see the information request below and provide a response by noon on May 9, 2017. As usual please provide the information in response to this e-mail and follow up by submitting the information as an official amendment to the BLA.

In your "registry protocol CCTL019B2401," you indicated that this protocol will include the collection of AEs reported in patients treated with tisagenlecleucel in accordance with the following Health Authority EMA and FDA guidance documents:

- FDA Guidance for Industry, "Gene Therapy Clinical Trials-Observing Subjects for Delayed Adverse Events", November 2006.
- FDA Guidance for Industry, "Supplemental Guidance on Testing for Replication Competent Retrovirus in Retroviral Vector Based Gene Therapy Products and

During Follow-up of Patients in Clinical Trials Using Retroviral Vectors", November 2006 update.

- FDA Guidance for Industry, "Consideration for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products", Draft Guidance July 2013.

Please provide the details regarding the approaches and time schedules for collecting clinical test sample, testing and monitoring for potential replication competent lentivirus (RCL) and vector persistence and clonality analysis.

Please confirm receipt of this request.

Thank you,

Erica Giordano
Regulatory Project Manager
Center for Biologics Evaluation and Research
Office of Tissues and Advanced Therapies
U.S. Food and Drug Administration
Tel: 240-402-8298
Erica.Giordano@fda.hhs.gov